<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05040282</url>
  </required_header>
  <id_info>
    <org_study_id>Implanon-nxt</org_study_id>
    <nct_id>NCT05040282</nct_id>
  </id_info>
  <brief_title>The Amenorrhea With Etonogestrel Implant</brief_title>
  <official_title>The Rate and Predictors of Amenorrhea at 1-year Follow-up in Women Using Etonogestrel Implant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The etonogestrel subdermal implant has been available worldwide for more than 15 years. The&#xD;
      action of etonogestrel subdermal implant is principal via suppression of ovulation, but it&#xD;
      also has effects on cervical mucus and in some women induces suppression of endometrial&#xD;
      proliferation. Several studies have confirmed its high efficacy and convenience. The uterine&#xD;
      bleeding problems and in particular irregular bleeding and amenorrhea are major side effects&#xD;
      of etonogestrel subdermal implant. A considerable number of patients request early removal&#xD;
      due to bleeding changes. Amenorrhea occurs in about 22% in etonogestrel subdermal implant&#xD;
      users. Despite the presence of many studies that reported the prevalence of etonogestrel&#xD;
      subdermal implant-associated bleeding, little is known about the predictive factors affecting&#xD;
      menstrual bleeding patterns especially amenorrhea after etonogestrel subdermal implant&#xD;
      insertion. These predictive factors should be provided prior to the etonogestrel subdermal&#xD;
      implant insertion which may improve acceptance and continuation of etonogestrel subdermal&#xD;
      implant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of women with amenorrhea after using etonogestrel subdermal implant</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Etonogestrel 68 mg implant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Women will be subjected to etonogestrel 68 mg implant insertion (Implanon NXT; Organon, USA Inc) according to manufacture instructions. The insertion will be within the first 5 days of the menstrual cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implanon NXT</intervention_name>
    <description>women will be subjected to etonogestrel 68 mg implant insertion. Participants will be trained on how to fill the menstrual diary. The menstrual diary includes information about days of bleeding and spotting days.</description>
    <arm_group_label>Etonogestrel 68 mg implant</arm_group_label>
    <other_name>Etonogestrel subdermal implant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women aged between 18 and 40 years.&#xD;
&#xD;
          2. Women who are not lactating.&#xD;
&#xD;
          3. Non-pregnant women&#xD;
&#xD;
          4. Women have regular menstrual cycles every 21-35 days with a typical cycle length&#xD;
             variation of no more than 5 days.&#xD;
&#xD;
          5. Women who will ESI only for pregnancy prevention for at least 12 months.&#xD;
&#xD;
          6. Have not any medical or gynecologic problems.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women with any contraindications for progesterone-only contraception in accordance&#xD;
             with WHO eligibility criteria.&#xD;
&#xD;
          2. Refuse participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Women Health Hospital - Assiut university</name>
      <address>
        <city>Assiut</city>
        <zip>71111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 21, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mohammed Khairy Ali</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etonogestrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

